Search
Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS Tumors
- OPACC
- Nov 28, 2024
- 1 min read
Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments